{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:50:10Z","timestamp":1790686210003,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T00:00:00Z","timestamp":1519344000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00280-018-3546-3","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T08:06:52Z","timestamp":1519373212000},"page":"783-789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Ibrutinib brain distribution: a preclinical study"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9741-803X","authenticated-orcid":false,"given":"Lauriane","family":"Goldwirt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Beccaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Ple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Sauvageon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Mourah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,23]]},"reference":[{"issue":"1","key":"3546_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/leu.2017.175","volume":"32","author":"JR Brown","year":"2018","unstructured":"Brown JR, Hillmen P, O\/\u2018Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC (2018) Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL. Leukemia 32(1):83\u201391","journal-title":"Leukemia"},{"issue":"6","key":"3546_CR2","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","volume":"126","author":"ML Wang","year":"2015","unstructured":"Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S (2015) Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 126(6):739\u2013745","journal-title":"Blood"},{"issue":"8","key":"3546_CR3","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1093\/annonc\/mdt139","volume":"24","author":"CY Cheah","year":"2013","unstructured":"Cheah CY, George A, Gin\u00e9 E, Chiappella A, Kluin-Nelemans HC, Jurczak W, Krawczyk K, Mocikova H, Klener P, Salek D, Walewski J, Szymczyk M, Smolej L, Auer RL, Ritchie DS, Arcaini L, Williams ME, Dreyling M, Seymour JF (2013) Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network\u2020. Ann Oncol 24(8):2119\u20132123","journal-title":"Ann Oncol"},{"issue":"4","key":"3546_CR4","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3324\/haematol.2015.136556","volume":"101","author":"P Strati","year":"2016","unstructured":"Strati P, Uhm JH, Kaufmann TJ, Nabhan C, Parikh SA, Hanson CA, Chaffee KG, Call TG, Shanafelt TD (2016) Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia. Haematologica 101(4):458\u2013465","journal-title":"Haematologica"},{"issue":"1","key":"3546_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1212\/WNL.46.1.19","volume":"46","author":"SC Cramer","year":"1996","unstructured":"Cramer SC, Glaspy JA, Efird JT, Louis DN (1996) Chronic lymphocytic leukemia and the central nervous system: a clinical and pathological study. Neurology 46(1):19\u201325","journal-title":"Neurology"},{"issue":"22","key":"3546_CR6","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood.V128.22.783.783","volume":"128","author":"C Grommes","year":"2016","unstructured":"Grommes C, Pastore A, Gavrilovic I, Kaley T, Nolan C, Omuro AM, Wolfe J, Pentsova E, Hatzoglou V, Mellinghoff I, DeAngelis L (2016) Single-agent Ibrutinib in recurrent\/refractory central nervous system lymphoma. Blood 128(22):783\u2013783","journal-title":"Blood"},{"key":"3546_CR7","volume-title":"Promising results of Ibrutinib in three patients with secondary central nervous system mantle cell lymphoma","author":"S Bernard","year":"2014","unstructured":"Bernard S, Goldwirt L, Amorim S, Brice P, Briere J, Sauvageon H, Thieblemont C (2014) Promising results of Ibrutinib in three patients with secondary central nervous system mantle cell lymphoma In. American Society of Heamatology, San Francisco"},{"issue":"6","key":"3546_CR8","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","volume":"31","author":"MS Lionakis","year":"2017","unstructured":"Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, Yang Y, Cole DE, Melani C, Higham CS, Desai JV, Ceribelli M, Chen L, Thomas CJ, Little RF, Gea-Banacloche J, Bhaumik S, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Heiss J, Lucas N, Steinberg SM, Staudt LM, Wilson WH (2017) Inhibition of B cell receptor signaling by Ibrutinib in primary CNS lymphoma. Cancer Cell 31(6):833\u2013843.e835","journal-title":"Cancer Cell"},{"issue":"10","key":"3546_CR9","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/0006-2952(95)02073-X","volume":"50","author":"L Jett\u00e9","year":"1995","unstructured":"Jett\u00e9 L, Murphy GF, Leclerc J-M, B\u00c8liveau R (1995) Interaction of drugs with P-glycoprotein in brain capillaries. Biochem Pharmacol 50(10):1701\u20131709","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"3546_CR10","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1172\/JCI118699","volume":"97","author":"AH Schinkel","year":"1996","unstructured":"Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97(11):2517\u20132524","journal-title":"J Clin Invest"},{"issue":"13 Supplement","key":"3546_CR11","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1158\/1538-7445.AM2017-5218","volume":"77","author":"SV Hoppe","year":"2017","unstructured":"Hoppe SV, Rood G-J, Wagenaar E, Sparidans R, Beijnen J, Schinkel A (2017) Abstract 5218: breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1) transport ibrutinib and may restrict its oral availability and brain accumulation, whereas CYP3A4 limits ibrutinib oral availability. Can Res 77(13 Supplement):5218\u20135218","journal-title":"Can Res"},{"issue":"24","key":"3546_CR12","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.1111\/bph.12889","volume":"171","author":"H Zhang","year":"2014","unstructured":"Zhang H, Patel A, Ma S-L, Li XJ, Zhang Y-K, Yang P-Q, Kathawala RJ, Wang Y-J, Anreddy N, Fu L-W, Chen Z-S (2014) In vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1. Br J Pharmacol 171(24):5845\u20135857","journal-title":"Br J Pharmacol"},{"key":"3546_CR13","unstructured":"FDA (2013) Clinical pharmacology and pharmacology reviews Ibrutinib\u2014Application number 205552Orig1s000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/205552Orig1s000ClinPharmR.pdf . Accessed 22 Feb 2018"},{"key":"3546_CR14","doi-asserted-by":"crossref","unstructured":"Mannina D, Loteta B (2017) Ibrutinib treatment of mantle cell lymphoma relapsing at central nervous system: a case report and literature review. Case Rep Hematol 2017:1\u20134, Article ID 9583257","DOI":"10.1155\/2017\/9583257"},{"issue":"1","key":"3546_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/FTD.0000000000000357","volume":"39","author":"HH Huynh","year":"2017","unstructured":"Huynh HH, Pressiat C, Sauvageon H, Madelaine I, Maslanka P, Lebbe C, Thieblemont C, Goldwirt L, Mourah S (2017) Development and validation of a simultaneous quantification method of 14 tyrosine kinase inhibitors in human plasma using LC-MS\/MS. Ther Drug Monit 39(1):43\u201354","journal-title":"Ther Drug Monit"},{"issue":"3","key":"3546_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF01062139","volume":"16","author":"AJ Bailer","year":"1988","unstructured":"Bailer AJ (1988) Testing for the equality of area under the curves when using destructive measurement techniques. J Pharm Biopharm 16(3):303\u2013309","journal-title":"J Pharm Biopharm"},{"issue":"13","key":"3546_CR17","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood-2014-08-593137","volume":"125","author":"I Sagiv-Barfi","year":"2015","unstructured":"Sagiv-Barfi I, Kohrt HE, Burckhardt L, Czerwinski DK, Levy R (2015) Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma. Blood 125(13):2079\u20132086","journal-title":"Blood"},{"key":"3546_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jct.2015.04.014","volume":"89","author":"F Shakeel","year":"2015","unstructured":"Shakeel F, Salem-Bekhit MM, Iqbal M, Haq N (2015) Solubility and thermodynamic function of a new anticancer drug ibrutinib in 2-(2-ethoxyethoxy)ethanol + water mixtures at different temperatures. J Chem Thermodyn 89:159\u2013163","journal-title":"J Chem Thermodyn"},{"issue":"6","key":"3546_CR19","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1080\/10915810600961531","volume":"25","author":"SC Gad","year":"2006","unstructured":"Gad SC, Cassidy CD, Aubert N, Spainhour B, Robbe H (2006) Nonclinical vehicle use in studies by multiple routes in multiple species. Int J Toxicol 25(6):499\u2013521","journal-title":"Int J Toxicol"},{"issue":"22","key":"3546_CR20","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1182\/blood.V128.22.4170.4170","volume":"128","author":"F Pouzoulet","year":"2016","unstructured":"Pouzoulet F, Rezai K, Li Z, Yushi Q, Tun HW, Labiod D, Bonnet-Boissinot S, Soussain C (2016) Preclinical evaluation of Ibrutinib for central nervous system lymphoma. Blood 128(22):4170\u20134170","journal-title":"Blood"},{"key":"3546_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1756-8722-6-59","volume":"6","author":"A Akinleye","year":"2013","unstructured":"Akinleye A, Chen Y, Mukhi N, Song Y, Liu D (2013) Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol 6:59\u201359","journal-title":"J Hematol Oncol"},{"issue":"2","key":"3546_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3324\/haematol.2016.149120","volume":"102","author":"F-J Pe\u00f1alver","year":"2017","unstructured":"Pe\u00f1alver F-J, Sancho J-M, de la Fuente A, Olave M-T, Mart\u00edn A, Panizo C, P\u00e9rez E, Salar A, Orfao A (2017) Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO). Haematologica 102(2):235\u2013245","journal-title":"Haematologica"},{"issue":"5","key":"3546_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/foc.2006.21.5.5","volume":"21","author":"JL Go","year":"2006","unstructured":"Go JL, Sandy C, Lee a PE, Kim (2006) Imaging of primary central nervous system lymphoma. Neurosurg Focus 21(5):1\u20136","journal-title":"Neurosurg Focus"},{"issue":"22","key":"3546_CR24","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1182\/blood.V128.22.5384.5384","volume":"128","author":"C Bonnet","year":"2016","unstructured":"Bonnet C, Lamy T, Fruchart C, Le Gouill S, Gunzer K, Gastinne T, Jardin F, Karlin L, Houot R, Dupuis J, Tilly H, Salles GA (2016) Ibrutinib in association with R-DHAP\/Ox for patients with relapsed\/refractory B-cell lymphoma: preliminary results of the Biblos Phase Ib Lysa Study. Blood 128(22):5384\u20135384","journal-title":"Blood"},{"issue":"22","key":"3546_CR25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1182\/blood.V128.22.150.150","volume":"128","author":"P Martin","year":"2016","unstructured":"Martin P, Blum K, Bartlett NL, Park SI, Maddocks KJ, Ruan J, Di Liberto M, Huang X, Inghirami G, Harris P, Chen-Kiang S, Leonard JP (2016) A phase I trial of Ibrutinib Plus Palbociclib in patients with previously treated mantle cell lymphoma. Blood 128(22):150\u2013150","journal-title":"Blood"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3546-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3546-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3546-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T15:41:36Z","timestamp":1603899696000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3546-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,23]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["3546"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3546-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,23]]},"assertion":[{"value":"27 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures involving animals were conducted in strict adherence to the French law for animal care and handling. (Authorization no. 2015071616316531.01).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}